Illumina Predicts 'Reacceleration' of Array Demand in 2010 as Sequencing Sales Buoy Revenue Growth

CEO Jay Flatley attributed a "faster than expected slowdown" in the San Diego firm's array business to researchers delaying new rounds of genome-wide association studies. Customers are also waiting to see if their projects will receive stimulus funding, he said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.